Marin County Public Health Status Update for August 25, 2023, includes Nationally Emerging Variant Detected in Marin: EG.5; Local HIV Dashboard Launched; August 31st: International Overdose Awareness Day; New RSV Immunization for Infants; and COVID-19 Data Update.
Para leer esta página en español, desplácese hacia arriba y haga clic en el enlace que dice "Translate" (Traducir) y elija "Spanish" (español).
The Marin County Public Health Status Update is published weekly to share news and resources related to pandemic response and recovery, emergency preparedness, and other public health priorities.
Nationally Emerging Variant Detected in Marin: EG.5
Marin COVID-19 Level remains in the orange, or medium tier, as transmission and hospitalizations rise. An increasingly common variant nationally, EG.5, also called "Eris," surfaced in Marin in late June and remains active here at low levels. Eris is not considered to be more serious than other variants and is part of the XBB family. The anticipated new fall booster is designed to protect against XBB strains.
Local HIV Dashboard Launched
Marin County's new HIV dashboard tracks local trends and provides insights into control. HIV in Marin is mainly transmitted through male-to-male and heterosexual sex. HIV can be managed with prevention and medical care. Around 600 Marin residents have HIV, with about 16 new cases annually. For more information about HIV visit CDC’s HIV homepage.
August 31st: International Overdose Awareness Day
Marin is battling an overdose crisis affecting all communities. For International Overdose Awareness Day, Michelle Leopold, owner of ACE Marin hardware and mother of Trevor who died from fentanyl overdose, will be hosting a training in Narcan use at her store. See Michelle’s story in this video. The county-wide “Where’s the Fentanyl” campaign is designed to raise awareness and invites residents to be part of the solution at ODFreeMarin.org.
New RSV Immunization for Infants
Some infants will be eligible to receive a new RSV immunization this fall. Nirsevimab (BeyfortusTM), is a long-acting antibody that cuts RSV hospitalizations by 80%. CDC recommends it for infants under 8 months and high-risk older babies. Families with infants under 2 years should contact their pediatrician to determine if the immunization is right for them. Learn more at RSV in Infants and Young Children | CDC.
COVID-19 Data Update
Actively Circulating Variants
Marin County COVID-19 Hospitalizations
Hospitalized COVID-19 Confirmed Patients
|Patients Hospitalized "for" COVID-19 Disease
|ICU Daily COVID-19 Patient Census
Settings Experiencing Outbreaks
Long-Term Care and Congregate Living Facilities
Resource Link Library
What to do if...